论文部分内容阅读
目的:研究ASPP蛋白在非小细胞肺癌中的表达情况,探讨其表达与患者预后之间的关系。方法:选取于我院就诊的86例非小细胞肺癌患者,病理学诊断癌症分型及分期,对所有患者进行随访,并用免疫组化法检测患者组织切片中ASPP2、i ASPP和p53的表达,SPSS软件分析ASPP2、i ASPP表达水平与患者预后的关系。结果:NSCLCⅢ期的患者中ASPP2阳性表达的中位生存期大于阴性患者,i ASPP阴性表达患者的中位生存期大于阳性患者(P<0.05);p53野生型Ⅲ期患者ASPP2阳性表达者的中位生存期显著大于阴性表达患者,Ⅰ、Ⅲ期i ASPP阴性表达患者的中位生存期显著大于阳性表达患者义(P<0.05)。p53突变型患者Ⅲ期iASPP阴性表达患者的中位生存期显著大于阳性表达患者(P<0.05)。ASPP2和i ASPP蛋白的表达水平和治疗方式均为影响患者预后的因素(P<0.05)。结论:ASPP2的阳性表达和i ASPP的阴性表达是NSCLC的保护因素,可在一定程度上预测患者的生存期。
Objective: To investigate the expression of ASPP protein in non-small cell lung cancer (NSCLC) and to explore the relationship between its expression and prognosis. Methods: Totally 86 patients with non-small cell lung cancer who were treated in our hospital were enrolled. Pathological diagnosis of cancer type and stage was performed. All patients were followed up. ASPP2, i ASPP and p53 were detected by immunohistochemistry. SPSS software analysis ASPP2, i ASPP expression levels and prognosis of patients. Results: The median survival time of ASPP2 positive patients in stage Ⅲ NSCLC was longer than that in negative patients. The median survival time of patients with negative ASPP2 was significantly higher than that of negative patients (P <0.05). In p53 wild type Ⅲ patients, The median survival time of patients with stage I and stage III ASPP was significantly higher than that of patients with positive expression (P <0.05). The median survival of stage Ⅲ iASPP negative patients with p53 mutant was significantly higher than that of positive patients (P <0.05). The expression levels of ASPP2 and i ASPP protein and the treatment methods were the factors affecting the prognosis of patients (P <0.05). Conclusion: The positive expression of ASPP2 and the negative expression of i ASPP are the protective factors of NSCLC, which can predict the survival of patients to a certain extent.